QUOTE AND NEWS
newratings.com  10 hrs ago  Comment 
THOUSAND OAKS (dpa-AFX) - The FDA has turned down Amgen Inc.'s (AMGN) Parsabiv, proposed for the treatment of secondary hyperparathyroidism in adult patients with chronic kidney disease on hemodialysis. Secondary hyperparathyroidism, or...
newratings.com  Aug 24  Comment 
WASHINGTON (dpa-AFX) - Hemispherx Biopharma Inc. (HEB) announced that it has received approval of its New Drug Application or NDA from Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica or ANMAT for commercial sale of...
newratings.com  Aug 23  Comment 
BUENOS AIRES (dpa-AFX) - Hemispherx Biopharma, Inc. (HEB) said it has received approval of its New Drug Application or NDA from Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica or ANMAT for commercial sale of rintatolimod in...
newratings.com  Jul 14  Comment 
WASHINGTON (dpa-AFX) - Hemispherx Biopharma, Inc. (HEB) announced key elements of its strategic growth plan as well as additional measures being implemented under its commitment to transparency. The aim of both the strategic growth plan and...





You may also be interested in articles related to Hemispherx BioPharma (HEB):

 
TOP CONTRIBUTORS
Hemispherx Biopharma, Inc (HEB) is a medical research company focusing on a new group of medicinal products knows as nucleic acid compounds.

HEB’s main focus is the treatment of Influenza and various Flu Strains through Ampligen®. However, Ampligen® may also serve as a treatment for Chronic Fatigue Syndrome (CFS). Ampligen®, the company’s main candidate is expected to receive FDA approval in the coming weeks. Other projects include Alferon N® which works as an indicator for recurring herpes.

Lack of diversified products, alternative remedies, failure to be approved by the FDA, and possible lawsuits from patients after approval, make this a very high risk company. But if approval by the FDA and wide acceptance of doctors world wide is accomplished many investors expect the stock value to rise too significantly too pass this investment by.

It is a New York City based corporation trading on AMEX.



References

http://www.google.com/finance?q=heb , http://www.hemispherx.net , http://www.pr-inside.com/post-approval-hemispherx-ampligen-pps-r1293461.htm ,

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki